Ex-JNJ exec to lead TuHURA Biosciences program

TuHURA Biosciences has appointed Dr. Craig Tendler, formerly JNJ's Global Head of Oncology Clinical Development, to lead its VISTA Program. This program focuses on developing novel therapeutics for Acute Myeloid Leukemia (AML) and other blood-related cancers. Dr. Tendler's extensive experience in oncology drug development is expected to significantly advance TuHURA's research and clinical trial efforts. His leadership marks a crucial step in the company's mission to create innovative treatments for challenging hematological malignancies. This strategic hire signals strong confidence in TuHURA's pipeline and its potential to impact patient outcomes.